ANI Pharmaceuticals has signed a binding letter of intent with Sofgen Pharmaceuticals to develop and market an oral soft gel prescription product indicated for cardiovascular health.
Development, manufacturing and regulatory activities of the product will be carried out by Sofgen and is subject to an Abbreviated New Drug Application (ANDA) filing.
ANI will take up marketing and distribution activities concerning the product in the US.
Commenting on the deal, ANI president and CEO Arthur Przybyl said, "In addition to our internal product development efforts, we will continue to pursue opportunities through external partnerships and acquisitions in order to leverage our core capabilities in manufacturing and marketing."
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/ani-pharmaceuticals-signs-deal-to-develop-oral-soft-gel-prescription-product-130813
